The reduced antibody response to COVID-19 vaccine is likely due to the well-known effect of the CTLA-4-Ig and TNF-α inhibitors on the reduction of the frequency of MBCs in the human peripheral blood (43–45). The gene discussed is CTLA4; the disease is COVID-19.